KIDNEY DISEASE AND HYPERTENSION IN BLACKS

描述(直接从应用程序中获取) 这项建议是对RFA DK-94003的回应，非裔美国人研究 肾脏疾病和高血压(AASK)；全面试验。这个 埃默里大学和莫尔豪斯医学院的申请者是 目前AASK试点试验的合作参与者。 第一阶段(94年7月至96年6月)为期24个月，招聘65人 记录在案的非裔美国人舒张期高血压(HBP)患者 并降低肾功能。这65名患者将被随机分成一组 三种治疗手段：β受体阻滞剂、血管紧张素转换酶 抑制剂或钙通道阻滞剂 治疗组控制两个水平的平均动脉压 (MAP)：通常(MAP 102-107 mm Hg)和紧凑(MAP小于或等于92 RNM汞)。第十一期(九六年七月至二零零零年六月)为期48个月 血压和肾脏系列评估的干预和患者随访 功能(125I-硫代巴比妥酸盐GFR测量)。第111期(2000年7月至6月 2001)是临床中心关闭、数据分析的12个月期间 并报告结果。 为了实现RFA、埃默里大学和莫尔豪斯的目标 医学院提供一支目前活跃的团队，在 招募少数族裔参与者参加临床试验，工作人员 接受肾小球滤过率技术培训，掌握精确的血液和尿液计时 标本，以及在变量研究方面具有专业知识的调查人员 对高血压患者肾脏疾病进展的影响。这个 结果将提高对高血压过度的理解-- 与非裔美国人相关的终末期肾病，并提供 适当的降压药物治疗指南。

DESCRIPTION (taken directly from the application) This proposal is in response to RFA DK-94003, African American Study of Kidney Disease and Hypertension (AASK); Full Scale Trial. The applicants, Emory University and Morehouse School of Medicine, are collaborative participants in the current AASK Pilot Trial. Phase I (Jul 94 - Jun 96) is a 24-month period for recruitment of 65 African American patients with documented diastolic hypertension (HBP) and reduced renal function. These 65 patients will be randomized to one of three treatment arms: beta blocker, angiotensin converting enzyme inhibitor, or calcium channel blocker with assignment within each treatment group to two levels of control of mean arterial blood pressure (MAP): usual (MAP 102-107 mm Hg) and tight (MAP less than or equal to 92 rnm Hg). Phase 11 (Jul 96 - Jun 2000) is a 48-month period for intervention and patient follow-up with serial assessment of BP and renal function (125I-iothalamate GFR measurements). Phase 111 (Jul 2000 - Jun 2001) is a 12-month period for clinical center close-out, data analysis and reporting results. To accomplish the objectives of the RFA, Emory University and Morehouse School of Medicine offer a currently active team highly experienced in recruitment of minority participants into clinical trials, a staff trained in GFR techniques with precise timing of blood and urine specimens, and investigators with expertise in research on variables that influence progression of renal disease in hypertensive patients. The results will improve the understanding of the excess of hypertension- related end-stage renal disease in African Americans, and provide guidelines for appropriate antihypertensive drug therapy.